Codexis, Inc. (0I0X.L)
USD 5.58
(-2.26%)
USD 5.58
(-2.26%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -43.27 Million USD | 38.49% |
| 2022 | -70.34 Million USD | -1.74% |
| 2021 | -69.14 Million USD | 44.31% |
| 2020 | -124.16 Million USD | -92.86% |
| 2019 | -64.38 Million USD | -21.52% |
| 2018 | -52.97 Million USD | -71.36% |
| 2017 | -30.91 Million USD | -64.32% |
| 2016 | -18.81 Million USD | 17.65% |
| 2015 | -22.84 Million USD | 13.74% |
| 2014 | -26.48 Million USD | -19.69% |
| 2013 | -22.13 Million USD | 30.85% |
| 2012 | -32 Million USD | -24.23% |
| 2011 | -25.76 Million USD | 64.42% |
| 2010 | -72.39 Million USD | -203.64% |
| 2009 | -23.84 Million USD | -178.7% |
| 2008 | -8.55 Million USD | 77.29% |
| 2007 | -37.66 Million USD | -33.7% |
| 2006 | -28.17 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -8.82 Million USD | -81.24% |
| 2024 Q1 | -15.35 Million USD | 64.52% |
| 2024 Q2 | 23.42 Million USD | 252.58% |
| 2023 FY | -43.27 Million USD | 38.49% |
| 2023 Q1 | -60.49 Million USD | 14.01% |
| 2023 Q4 | -43.27 Million USD | 20.75% |
| 2023 Q3 | -54.59 Million USD | -6.87% |
| 2023 Q2 | -51.08 Million USD | 15.55% |
| 2022 Q2 | -44 Million USD | 6.33% |
| 2022 Q1 | -46.97 Million USD | 32.06% |
| 2022 Q4 | -70.34 Million USD | -10.25% |
| 2022 Q3 | -63.8 Million USD | -45.0% |
| 2022 FY | -70.34 Million USD | -1.74% |
| 2021 Q4 | -69.14 Million USD | 28.12% |
| 2021 FY | -69.14 Million USD | 44.31% |
| 2021 Q3 | -96.18 Million USD | 9.12% |
| 2021 Q2 | -105.84 Million USD | 8.31% |
| 2021 Q1 | -115.42 Million USD | 7.04% |
| 2020 Q4 | -124.16 Million USD | -170.16% |
| 2020 FY | -124.16 Million USD | -92.86% |
| 2020 Q1 | -61.18 Million USD | 4.96% |
| 2020 Q2 | -49.5 Million USD | 19.09% |
| 2020 Q3 | -45.96 Million USD | 7.15% |
| 2019 Q2 | -66.4 Million USD | -234.45% |
| 2019 FY | -64.38 Million USD | -21.52% |
| 2019 Q4 | -64.38 Million USD | 1.82% |
| 2019 Q3 | -65.57 Million USD | 1.26% |
| 2019 Q1 | -19.85 Million USD | 62.52% |
| 2018 Q2 | -53.01 Million USD | -124.33% |
| 2018 FY | -52.97 Million USD | -71.36% |
| 2018 Q3 | -53.67 Million USD | -1.25% |
| 2018 Q4 | -52.97 Million USD | 1.3% |
| 2018 Q1 | -23.63 Million USD | 23.56% |
| 2017 Q2 | -28.39 Million USD | -107.77% |
| 2017 Q3 | -23.46 Million USD | 17.37% |
| 2017 Q1 | -13.66 Million USD | 27.36% |
| 2017 Q4 | -30.91 Million USD | -31.75% |
| 2017 FY | -30.91 Million USD | -64.32% |
| 2016 Q2 | -21.25 Million USD | -1.41% |
| 2016 FY | -18.81 Million USD | 17.65% |
| 2016 Q1 | -20.95 Million USD | 8.27% |
| 2016 Q4 | -18.81 Million USD | -35.11% |
| 2016 Q3 | -13.92 Million USD | 34.48% |
| 2015 Q3 | -16.96 Million USD | -2.2% |
| 2015 Q4 | -22.84 Million USD | -34.69% |
| 2015 Q2 | -16.59 Million USD | 25.1% |
| 2015 FY | -22.84 Million USD | 13.74% |
| 2015 Q1 | -22.15 Million USD | 16.34% |
| 2014 FY | -26.48 Million USD | -19.69% |
| 2014 Q4 | -26.48 Million USD | -23.07% |
| 2014 Q1 | -23.16 Million USD | -4.67% |
| 2014 Q2 | -20.09 Million USD | 13.27% |
| 2014 Q3 | -21.52 Million USD | -7.13% |
| 2013 Q2 | -32.39 Million USD | -3.72% |
| 2013 Q4 | -22.13 Million USD | 17.77% |
| 2013 FY | -22.13 Million USD | 30.85% |
| 2013 Q1 | -31.23 Million USD | 2.41% |
| 2013 Q3 | -26.91 Million USD | 16.92% |
| 2012 Q3 | -25.57 Million USD | -53.2% |
| 2012 Q2 | -16.69 Million USD | 37.25% |
| 2012 Q1 | -26.6 Million USD | -3.27% |
| 2012 FY | -32 Million USD | -24.23% |
| 2012 Q4 | -32 Million USD | -25.14% |
| 2011 Q1 | -53.15 Million USD | 26.58% |
| 2011 Q4 | -25.76 Million USD | 14.5% |
| 2011 Q3 | -30.13 Million USD | 6.08% |
| 2011 Q2 | -32.08 Million USD | 39.64% |
| 2011 FY | -25.76 Million USD | 64.42% |
| 2010 Q1 | -22.53 Million USD | 5.49% |
| 2010 Q3 | -95.24 Million USD | -106.84% |
| 2010 Q4 | -72.39 Million USD | 23.99% |
| 2010 FY | -72.39 Million USD | -203.64% |
| 2010 Q2 | -46.04 Million USD | -104.33% |
| 2009 FY | -23.84 Million USD | -178.7% |
| 2009 Q4 | -23.84 Million USD | -81.47% |
| 2009 Q3 | -13.13 Million USD | 0.0% |
| 2008 FY | -8.55 Million USD | 77.29% |
| 2008 Q4 | -8.55 Million USD | 0.0% |
| 2008 Q1 | -11.04 Million USD | 0.0% |
| 2007 FY | -37.66 Million USD | -33.7% |
| 2006 FY | -28.17 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 126.753% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | 1111.005% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 47.088% |
| Organovo Holdings, Inc. | -1.5 Million USD | -2771.334% |